XML 84 R73.htm IDEA: XBRL DOCUMENT
v3.23.2

Commitments and Contingencies - Schedule of Unfunded Contractual Commitments (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022
--- | --- | ---
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1],[2] | $ 381,104 | $ 628,874
Investment Funds And Vehicles |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1],[2] | 5,017 | 5,653
Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 376,087 | 623,221
Phathom Pharmaceuticals, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 16,625 | 66,500
Vida Health | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 3,000 | 40,000
Skydio, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 22,500 | 22,500
SeatGeek, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 19,375 | 0
Oak Street Health, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 33,750
HilleVax, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 28,000
Axsome Therapeutics, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 25,375 | 21,000
Automation Anywhere, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 29,400 | 29,400
Iveric Bio Gene Therapy LLC | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 12,375 | 0
Aryaka Networks, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 10,000 | 20,000
G1 Therapeutics, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 19,375
Dragos | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 13,000 | 0
Alladapt Immunotherapeutics Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 15,000
Dronedeploy Incorporation | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 12,500 | 12,500
Locus Robotics Corporation | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 10,740 | 0
R V Share Limited Liability Company | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 1,500 | 1,500
App Direct Incorporation | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 15,000
Nuvolo Technologies Corporation | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 5,700 | 5,970
Elation Health, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 7,500 | 7,500
Gritstone Bio, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 7,500 | 7,500
Viridian Therapeutics Inc | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 12,000
Tarsus Pharmaceuticals, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 8,250 | 10,313
Dashlane, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 10,000
Akero Therapeutics, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 5,000 | 5,000
Alamar Biosciences, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 10,000 | 10,000
Fulfil Solutions Inc [Member] | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 5,000
Brain Corporation | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 2,500 | 20,700
Ceros, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 1,707 | 1,707
Demandbase, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 3,750
Riviera Partners LLC | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 3,500 | 3,500
Signal Media Limited [Member] | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 3,000 | 5,250
Yipit, LLC | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 2,250 | 2,250
Saama Technologies | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 3,875 | 0
Khoros (p.k.a Lithium Technologies) | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 906 | 1,812
ThreatConnect, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 1,600 | 1,600
Dispatch Technologies, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 1,250 | 1,250
Logic Source | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 1,209 | 1,209
Ikon Science Limited | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 1,050 | 1,050
Omeda Holdings, LLC | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 919 | 938
Alchemer LLC | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 445 | 890
3GTMS, LLC | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 1,222 | 0
Agilence, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 800 | 800
Constructor.io Corporation [Member] | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 625 | 625
Mobile Solutions Services | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 495
Enmark Systems, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 457 | 457
Zimperium, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 1,088 | 1,088
Cybermaxx Intermediate Holdings, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 390 | 390
ShadowDragon, LLC | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 333 | 333
Cytracom Holdings LLC | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 72 | 225
Annex Cloud | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 386 | 386
Thumbtack, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 40,000 | 40,000
Madrigal Pharmaceutical Inc [Member] | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 34,000
TG Therapeutics, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 6,500 | 0
Sumo Logic | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 2,000 | 0
Carwow LTD | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 14,365 | 0
Forbion Growth Opportunities Fund I C V | Investment Funds And Vehicles |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1],[2] | 2,269 | 2,842
Streamline Healthcare Solutions | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 2,200 | 0
Forbion Growth Opportunities Fund I I C V | Investment Funds And Vehicles |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1],[2] | 2,748 | 2,811
Tipalti Solutions Ltd. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 10,500 | 0
Next Insurance, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 10,000 | 0
FeverLabsInc | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 8,333
Kura Oncology, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 8,250 | 8,250
MacroFab, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 3,000
Zappi, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 2,571 | 2,571
Cutover, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 4,150 | 1,000
Fortified Health Security | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 840 | 840
Flight Schedule Pro, LLC | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 639 | 639
ReplimuneGroupInc | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 20,700
Pathai Inc | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 12,000 | 12,000
Leapwork ApS | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 4,100 | 0
Provention Bio, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 0 | 40,000
BabelStreet | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 3,375 | 3,375
Modern Life, Inc. | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | 3,250 | 0
Loftware, Inc | Debt Investments |  |  |
Loss Contingencies [Line Items] |  |  |
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount | [1] | $ 1,423 | $ 0
[1] | For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $127.9 million and $173.5 million of unfunded commitments as of June 30, 2023, and December 31, 2022, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”.
[2] | For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.

X
- Definition Amount of financial support committed by investment company to investee that is contractually required but not provided. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-16 + Details
Name: | us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=htgc_InvestmentFundsAndVehiclesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=htgc_DebtInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PhathomPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_VidaHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SkydioIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SeatGeekIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_OakStreetHealthIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_HilleVaxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AxsomeTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AutomationAnyWhereIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_IvericBioGeneTherapyLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AryakaNetworksIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_G1TherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DragosMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AlladaptImmunotherapeuticsincMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DronedeployIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LocusRoboticsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RVShareLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AppDirectIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NuvoloTechnologiesCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ElationHealthIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_GritstoneBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ViridianTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TarsusPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DashlaneIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AkeroTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AlamarBiosciencesIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FulfilSolutionsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BrainCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CerosIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DemandbaseIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_RivieraPartnersLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SignalMediaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_YipitLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SaamaTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_KhorosPKLithiumTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ThreatConnectIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_DispatchTechnologiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LogicSourceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_IkonScienceLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_OmedaHoldingsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AlchemerLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ThreeGTMSLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AgilenceIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ConstructorIoCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MobileSolutionsServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_EnmarkSystemsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ZimperiumIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CybermaxxIntermediateHoldingsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ShadowDragonLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CytracomHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_AnnexCloudMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ThumbtackIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MadrigalPharmaceuticalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TGTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_SumoLogicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CarwowLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ForbionGrowthOpportunitiesFundICVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_StreamlineHealthcareSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ForbionGrowthOpportunitiesFundIICVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_TipaltiSolutionsLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_NextInsuranceIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FeverLabsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_KuraOncologyIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_MacroFabIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ZappiIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_CutoverIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FortifiedHealthSecurityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_FlightScheduleProLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ReplimuneGroupIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_PathaiIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LeapworkApsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ProventionBioIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_BabelStreetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_ModernLifeIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=htgc_LoftwareIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |